SCHEMBL13117118

SCHEMBL13117118

O=C(O)C(=O)c1c[nH]c2c(-n3cncn3)ncc(F)c12

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.50
CYP1A2 P05177 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP2C8 P10632 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2B6 P20813 1/20 0.35
KCNH2 Q12809 1/20 0.35
STING1 Q86WV6 1/20 0.33
POLB P06746 1/20 0.33
GLA P06280 1/20 0.32
HTT P42858 1/20 0.32
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
RAB9A P51151 1/20 0.30
RXFP1 Q9HBX9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2628880 0.86 CYP3A4 (0.52) CYP3A4CYP1A2CYP2C9CYP2C19CYP2C8
SCHEMBL1473310 0.83 CYP3A4 (0.69) CYP3A4CYP1A2CYP2C9CYP2C19CYP2C8
SCHEMBL2629098 0.81 CYP3A4 (0.77) CYP3A4CYP1A2CYP2C9CYP2C19CYP2C8
SCHEMBL15273632 0.81 CYP3A4 (0.51) CYP3A4CYP1A2CYP2C9CYP2C19CYP2C8
SCHEMBL15221339 0.80 CYP3A4 (0.34) CYP3A4CYP1A2CYP2C9CYP2C19CYP2C8
SCHEMBL12777844 0.79 CYP3A4 (0.43) CYP3A4HTTKDM4EALDH1A1
SCHEMBL1733111 0.79 NOTUM (0.33) CYP3A4CYP1A2CYP2C9CYP2C19CYP2C8
SCHEMBL12752582 0.77 CYP3A4 (0.58) CYP3A4CYP1A2CYP2C9CYP2C19CYP2C8
SCHEMBL1473128 0.76 CYP3A4 (0.58) CYP3A4CYP1A2CYP2C9CYP2C19CYP2C8
SCHEMBL15693026 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807676-B2 Diketo-Piperazine and Piperidine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-05 US disclosed
US-7807676-B2 Diketo-Piperazine and Piperidine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-05 US disclosed
US-7807671-B2 Diketo-piperazine and piperidine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-05 US disclosed
US-7807671-B2 Diketo-piperazine and piperidine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-05 US disclosed
US-20080139572-A1 DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY 2008-06-12 US disclosed
US-20080139572-A1 DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY 2008-06-12 US disclosed
US-20070249579-A1 DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed
US-20070249579-A1 DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139572-A1 DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS EIF2AK2, DCK, MAVS CYP3A4 1204/4885CYP1A2 2178/4885CYP2C9 3136/4885
US-20070249579-A1 DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS EIF2AK2, DCK, MAVS CYP3A4 1204/4885CYP1A2 2178/4885CYP2C9 3136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.